Ikarian Capital’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.37M Hold
809,741
– – 0.74% 33
2026
Q2
$5.35M Sell
809,741
-405,000
-33% -$2.79M 0.58% 53
2026
Q1
$8.79M Buy
1,214,741
+604,741
+99% +$4.87M 0.71% 38
2025
Q4
$4.61M Buy
+610,000
New +$3.76M 0.36% 66

Other funds holding EPRX

Ikarian Capital's EPRX Position: Q3 2026 in Review

Ikarian Capital held its Eupraxia Pharmaceuticals (EPRX) position steady in Q3 2026 at 809,741 shares worth $7.37M. The position accounts for 0.74% of the portfolio, ranked #33.

Ikarian Capital first reported a position in EPRX in Q4 2025 and has held it in 4 quarters since. The position peaked at $8.79M in Q1 2026. 70 funds tracked by Wall St. Rank hold EPRX as of Q3 2026.

  • Ikarian Capital held 809,741 shares of Eupraxia Pharmaceuticals worth $7.37M as of Q3 2026.
  • Ikarian Capital left its Eupraxia Pharmaceuticals share count unchanged in Q3 2026.
  • Eupraxia Pharmaceuticals made up 0.74% of Ikarian Capital's portfolio in Q3 2026, its #33 holding.
  • Ikarian Capital first reported a position in Eupraxia Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • Ikarian Capital's Eupraxia Pharmaceuticals position peaked at $8.79M in Q1 2026.
  • 70 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q3 2026.

Based on Ikarian Capital's 13F filing for Q3 2026, filed 16 Nov 2026.